or
forgot password

Lymphokine Activated Killer (LAK) Cell Activity Against Cell Lines In-vitro of LAK Generated in Vivo by Pulse Interleukin-2 Therapy


N/A
18 Years
N/A
Open (Enrolling)
Both
Melanoma, Kidney Cancer

Thank you

Trial Information

Lymphokine Activated Killer (LAK) Cell Activity Against Cell Lines In-vitro of LAK Generated in Vivo by Pulse Interleukin-2 Therapy


Blood samples will be taken from patients undergoing outpatient Interleukin-2 therapy to
measure the LAK cytotoxicity at baseline, after 1 cycle of therapy and 2 months later. The
LAK cytotoxicity assay will be a standard colorimetric assay that measures lactic
dehydrogenase release from lysed cells.


Inclusion Criteria:



- Patients must be undergoing Interleukin-2 therapy under the care of physicians at
Loma Linda University Cancer Center

- Patients must sign and give written informed consent in accordance with institutional
and federal guidelines

Exclusion Criteria:

- Patients not undergoing Interleukin-2 therapy under the care of physicians at Loma
Linda University Cancer Center

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

LAK cytotoxicity

Outcome Time Frame:

4 months

Safety Issue:

No

Principal Investigator

Walter Quan, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Loma Linda University

Authority:

United States: Institutional Review Board

Study ID:

59210

NCT ID:

NCT01068470

Start Date:

November 2009

Completion Date:

September 2012

Related Keywords:

  • Melanoma
  • Kidney Cancer
  • Interleukin-2
  • Melanoma
  • Kidney Cancer
  • Lymphokine Activated Killer cells
  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Melanoma

Name

Location
Loma Linda University Cancer Center Loma Linda, California  92354